Pharmacological or genetic inhibition of MAGL significantly increases 2-AG concentrations and alleviates Aβ-induced neurodegeneration and apoptosis, improving synaptic function and cognitive function in AD [230–234]. Here, MGLL is linked to Alzheimer disease.